Combining top-ranked immunotherapeutics in lung cancer

Lancet Oncol. 2018 May;19(5):592-594. doi: 10.1016/S1470-2045(18)30186-4. Epub 2018 Apr 5.

Authors

Christian Rolfo¹, Evelien L J Smits²

Affiliations

¹ Phase I- Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Antwerp, Belgium; Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium. Electronic address: christian.rolfo@uza.be.
² Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium; Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.

PMID: 29628313
DOI: 10.1016/S1470-2045(18)30186-4

No abstract available

Publication types

Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
Humans
Interleukin-15
Lung Neoplasms*
Nivolumab
Proteins
Recombinant Fusion Proteins

Substances

ALT-803
Interleukin-15
Proteins
Recombinant Fusion Proteins
Nivolumab